Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - lenalidomidum - gélules - lenalidomidum 15 mg à lenalidomidi hydrochloridum monohydricum, de la silice colloidalis anhydrica, cellulosum microcristallinum, carmellosum natricum seulement liés corresp. de sodium de 0,036 mg, talc, kapselhülle: gélatine, e 171, e 132, drucktinte: lacca, propylenglycolum, ammoniae solution de 30 à travers les centaines de e-172 (noir), kalii hydroxidum, pour une petite boîte. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - lenalidomidum - gélules - lenalidomidum 20 mg à lenalidomidi hydrochloridum monohydricum, de la silice colloidalis anhydrica, cellulosum microcristallinum, carmellosum natricum seulement liés corresp. sodium 0,048 mg, talc, kapselhülle: gélatine, e 171, e 172 (jaune), e 132, drucktinte: lacca, propylenglycolum, ammoniae solution de 30 à travers les centaines de e-172 (noir), kalii hydroxidum, pour une petite boîte. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

teva pharma ag - lenalidomidum - gélules - lenalidomidum 25 mg pour lenalidomidi hydrochloridum monohydricum, de la silice colloidalis anhydrica, cellulosum microcristallinum carmellosum natricum seulement liés corresp. sodium 0,06 mg, talc, kapselhülle: gélatine, e-171, drucktinte: lacca, propylenglycolum, ammoniae solution de 30 à travers les centaines de e-172 (noir), kalii hydroxidum, pour une petite boîte. - onkologikum - synthetika

Union européenne - français - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosuppresseurs - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 et 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) est indiqué pour le traitement de patients adultes atteints de traitement préalable de myélome multiple qui ne sont pas éligibles pour une transplantation. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 et 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 2.5 mg, lactosum 73.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.2 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 132, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 5 mg, lactosum 147 mg, cellulosum microcristallinum, carmellosum natricum seulement liés corresp. sodium 0,4 mg, magnésium stearas, kapselhülle: gélatine, e-171, drucktinte: lacca, propylenglycolum, e 172 (noir), kalii hydroxidum, pour une petite boîte. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 7.5 mg, lactosum 144.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 10 mg, lactosum 294 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 15 mg, lactosum 289 mg, cellulosum microcristallinum, carmellosum natricum seulement liés corresp. sodium 0,8 mg, magnésium stearas, kapselhülle: gélatine, e 171, e 132, drucktinte: lacca, propylenglycolum, e 172 (noir), kalii hydroxidum, pour une petite boîte. - onkologikum - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

bristol-myers squibb sa - lenalidomidum - gélules - lenalidomidum 20 mg, lactosum 244.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika